Leap Therapeutics Equity 2024

Leap Therapeutics Aktienanalyse

What does Leap Therapeutics do?

Leap Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. The company was founded in 2011 as HealthCare Pharmaceuticals Inc. and specializes in the development of new cancer therapies. The company's history began with the discovery of LIM kinase (LIMK) as a new target molecule for cancer therapies. This protein plays a role in the regulation of the cytoskeleton, which is important for cell shape and movement. Inhibiting LIMK could therefore inhibit the growth and spread of cancer cells. Leap Therapeutics has subsequently focused on the development of antibody therapies targeted against various types of cancer. The company employs a combination therapy approach, consisting of multiple drugs tailored to the specific characteristics of the tumor. The goal is to increase treatment efficacy while reducing potential side effects. Leap Therapeutics currently has several clinical trials underway, focusing on different types of cancer such as breast, lung, and colorectal cancer. A key focus is on developing therapies for patients with advanced or metastatic cancer for whom conventional treatment methods are no longer sufficient. One example of a Leap Therapeutics product is the antibody DKN-01, which targets the growth factors DKK1 and DKK2. These factors play a role in the regulation of tumor growth and metastasis and are elevated in many types of cancer. Clinical studies have shown that DKN-01 in combination with the chemotherapy drug paclitaxel has a higher response rate in patients with lung cancer compared to chemotherapy alone. Another Leap Therapeutics product is the antibody TRX518, which specifically targets the immune receptor OX40. OX40 plays a role in the activation of T lymphocytes, which are important in combating cancer cells. Clinical studies have shown that TRX518 can enhance response to cancer therapy and improve survival in patients with advanced melanoma. Leap Therapeutics' business model is based on the development and commercialization of novel therapeutics. The company collaborates closely with other biotech companies, as well as academic institutions and clinical centers, to accelerate the development of new therapies and bring them to market as quickly as possible. Overall, Leap Therapeutics is a promising biotechnology company specializing in the development of new cancer therapies. Through the targeted combination of drugs and the focus on specific target molecules, the aim is to develop highly effective therapies that offer advanced cancer patients better chances of survival and a higher quality of life. Leap Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Leap Therapeutics's Equity

Leap Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Leap Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Leap Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Leap Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Leap Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Leap Therapeutics Stock

What is the equity of Leap Therapeutics this year?

Leap Therapeutics has equity of 60.14 M USD this year.

What was the equity of Leap Therapeutics compared to the previous year?

The equity of Leap Therapeutics has increased/decreased by 2.11% increased compared to the previous year.

What impact does a high equity have on investors of Leap Therapeutics?

A high equity is advantageous for investors of Leap Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Leap Therapeutics?

A low equity can be a risk for investors of Leap Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Leap Therapeutics affect the company?

An increase in equity of Leap Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Leap Therapeutics affect the company?

A reduction in equity of Leap Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Leap Therapeutics?

Some factors that can affect the equity of Leap Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Leap Therapeutics so important for investors?

The equity of Leap Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Leap Therapeutics take to change the equity?

To change equity, Leap Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Leap Therapeutics pay?

Over the past 12 months, Leap Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Leap Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Leap Therapeutics?

The current dividend yield of Leap Therapeutics is .

When does Leap Therapeutics pay dividends?

Leap Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Leap Therapeutics?

Leap Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Leap Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Leap Therapeutics located?

Leap Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Leap Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Leap Therapeutics from 5/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/1/2024.

When did Leap Therapeutics pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of Leap Therapeutics in the year 2023?

In the year 2023, Leap Therapeutics distributed 0 USD as dividends.

In which currency does Leap Therapeutics pay out the dividend?

The dividends of Leap Therapeutics are distributed in USD.